Home > Back to Publisher > Report Information

Gilead Sciences Inc.: PharmaVitae Profile

Datamonitor
September 16, 2009
SKU: DFMN2445021

Abstract Table of Contents Search inside this report Related Reports

Introduction

This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Gilead's performance against key rivals in the prescription pharmaceutical sector
See how Gilead's HIV franchise will drive continued double-digit sales growth for the company out to 2014
Assess the impact of the company's recently announced collaboration with Tibotec for a 'second generation Atripla'

ABOUT DATAMONITOR HEALTHCARE: About the PharmaVitae team
Chapter 1 About this profile: PharmaVitae Explorer database; Chapter structure; Data sourcing
Chapter 2 Executive summary: Key findings; Prescription pharmaceutical sales and growth rate performance, 2002-14; Financial performance, 2002-14; Gilead Sciences: PharmaVitae forecasts at a glance; Strategic insight; SWOT analysis
Chapter 3 Quarterly news update: Product developments; Deals and alliances; M&A activity; Company announcements; Future product milestones
Chapter 4 Company introduction: Key findings; Background; Key corporate developments; M&A history
Chapter 5 Company sales: Key findings; Prescription pharmaceutical sales and growth rate analysis, 2002-14; Product analysis; Therapy area analysis; Geographic analysis; Launch/core/expiry analysis; Molecule type analysis; Externalization analysis
Chapter 6 Company financials: Key findings; Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08; Operating costs and profit analysis
Chapter 7 Key products and competitors: Key findings; Overview; Infectious diseases; Cardiovascular
Chapter 8 Appendix: R&D pipeline; References; Abbreviations; About Datamonitor; Datamonitor consulting; Disclaimer
List of Tables: Table 1: Gilead - PharmaVitae forecasts at a glance; Table 2: Gilead’s HIV franchise, 2008-14 ($m); Table 3: Gilead key product developments, 2009; Table 4: Gilead product deals and alliances, 2009; Table 5: Gilead technology deals and alliances, 2009; Table 6: Gilead M&A activity, 2009; Table 7: Gilead company announcements, 2009; Table 8: Gilead future product milestones, 2009-11; Table 9: Gilead product portfolio overview ($m), 2002-08; Table 10: Gilead product portfolio overview ($m), 2008-14; Table 11: Gilead prescription pharmaceutical sales by therapy area ($m), 2008-14; Table 12: Gilead prescription pharmaceutical sales by geographic region ($m), 2008-14; Table 13: Gilead launch portfolio overview ($m), 2008-14; Table 14: Gilead core portfolio overview ($m), 2008-14; Table 15: Gilead expiry portfolio overview ($m), 2008-14; Table 16: Gilead prescription pharmaceutical sales by molecule type ($m), 2008-14; Table 17: Gilead prescription pharmaceutical sales by source ($m), 2008-14; Table 18: Total Gilead sales by business unit ($m), 2002-08; Table 19: Gilead operating revenue/cost analysis ($m), 2002-08; Table 20: Gilead operating cost ratio analysis (% of total revenues), 2002-08; Table 21: Gilead operating cost ratio analysis (% of total revenues), 2008-14; Table 22: Gilead operating revenue/cost analysis ($m), 2008-14; Table 23: Key products overview; Table 24: Atripla: overview; Table 25: Atripla: sales forecast ($m), 2008-14; Table 26: Truvada: overview; Table 27: Truvada: sales forecast ($m), 2008-14; Table 28: Viread: overview; Table 29: Viread: sales forecast ($m), 2008-14; Table 30: Truvada + rilpivirine: overview; Table 31: Truvada + rilpivirine: sales forecast ($m), 2008-14; Table 32: Letairis: overview; Table 33: Letairis: sales forecast ($m), 2008-14; Table 34: Gilead Sciences R&D pipeline (Phase I-registration)
TABLE OF FIGURES: Figure 1: The PharmaVitae Explorer; Figure 2: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14; Figure 3: Gilead’s financial performance ($m), 2002-14; Figure 4: Sales of the leading HIV therapy players, 2002-14 ($m); Figure 5: Gilead prescription pharmaceutical sales by source, and therapy area ($m), 2002-14; Figure 6: Gilead SWOT analysis; Figure 7: Gilead prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14; Figure 8: Key product sales ($m), 2002-14; Figure 9: Gilead key sales growth drivers and resistors ($m), 2002-08; Figure 10: Gilead key sales growth drivers and resistors ($m), 2008-14; Figure 11: Gilead prescription pharmaceutical sales by therapy area ($m), 2002-14; Figure 12: Gilead prescription pharmaceutical sales by geographic region ($m), 2002-14; Figure 13: Gilead launch/core/expiry configuration ($m), 2008-14; Figure 14: Gilead prescription pharmaceutical sales by molecule type ($m), 2002-14; Figure 15: Gilead prescription pharmaceutical sales by source ($m), 2002-14; Figure 16: Gilead operating revenue/cost analysis ($m), 2002-14

Gilead Sciences Inc.: PharmaVitae Profile

Share this report

Other tasks

Research Assistance

Related Markets

G - Reports

Free Alert Me service